Screener
Cytokinetics CYTK Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Cytokinetics in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Cytokinetics’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 4:30 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001193125-26-338217
| Line item | June 30, 2026 | December 31, 2025 |
|---|---|---|
| Commitments and contingencies | ||
| Stockholders' deficit | ||
| Preferred stock | — | — |
| Common stock | 138 | 123 |
| Additional paid-in capital | 3,721,713 | 2,826,341 |
| Accumulated other comprehensive (loss) income | (3,826) | 630 |
| Accumulated deficit | (3,891,512) | (3,486,719) |
| Total stockholders' deficit | (173,487) | (659,625) |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Cytokinetics's common stock?
- Cytokinetics (CYTK) reported common stock of $138K in Q2 2026.
- How has Cytokinetics's common stock changed year-over-year?
- Cytokinetics's common stock increased by 16.0% year-over-year, from $119K to $138K.
- What is the long-term trend for Cytokinetics's common stock?
- Over 5 years (2020 to 2025), Cytokinetics's common stock has grown at a 11.9% compound annual growth rate (CAGR), from $70K to $123K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Cytokinetics's common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude